GCAN: The Greater Cannabis Company, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 0.64
Enterprise Value ($M) 1.02
Book Value ($M) -0.80
Book Value / Share -0.00
Price / Book -0.81
NCAV ($M) -0.80
NCAV / Share -0.00
Price / NCAV -0.81

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.06
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.07
Current Ratio 0.07

Balance Sheet (mrq) ($M)
Current Assets 0.06
Assets 0.06
Liabilities 0.86
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act Of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report Under Se
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act Of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report Under Section
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act Of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report Under Sectio
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2023 ☐ Transition Report Under Section 13

(click for more detail)

Similar Companies
FPMI – FluoroPharma Medical, Inc. FRTX – Fresh Tracks Therapeutics, Inc.
GBIM – GlobeImmune, Inc. GDERF – Galderma Group AG
GFOO – Genufood Energy Enzymes Corp.


Financial data and stock pages provided by
Fintel.io